MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
San Antonio, Texas
2026: OPMED 2026_Operational Medicine (OpMed) SYMPOSIUM & TECHNOLOGY SHOWCASE March 17-18 2026, San Antonio, Texas
Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF)
Organization & Developments: HJF (Henry M. Jackson Foundation)
HJF: Locations
Japan
Industry: Japan
Fujirebio Diagnostics, Inc.
Organization & Developments: Fujirebio Diagnostics
Parents
Fujirebio Diagnostics, Inc.
Children
*Fujirebio specializes in innovation, development, manufacturing, and marketing of in vitro diagnostics (IVD) testing reagents, instruments, and software for clinical diagnostics and for research use
*LUMIPULSE G ß-AMYLOID RATIO (1-42/1-40)
2022: FDA’s breakthrough device designations poised for another record year
2022: The 510(k) clearance of EarliTec Diagnostics’ EarliPoint Evaluation for autism spectrum disorder expanded the tools available to determine if children aged 16 to 30 months have ASD.
2022: The FDA granted De Novo marketing authorization for Fujirebio Diagnostics’ Lumipulse G β-Amyloid Ratio in vitro diagnostic test.
2022: The test can assess beta-amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test is the first authorized by the FDA to support the assessment of Alzheimer’s.
2024: As new Alzheimer’s biomarkers come into play, here’s where the money is going
2025: FDA endorses first-of-its-kind blood test for Alzheimer’s disease
2025: FDA greenlights first blood test to diagnose Alzheimer's disease
2025: Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
2026: The new Alzheimer’s blood test: What it means for diagnosis
Jumps
Finance & Acquisitions: Fujirebio Diagnostics
Key People: Fujirebio Diagnostics